Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.
Michelle is a mother of 2 and who has worked in elementary education. Her cancer advocacy journey started in 2017 after she was diagnosed with two primary cancers…de novo metastatic breast cancer and thyroid cancer. At the time, she was trying to make a decision about her reconstruction options, and quickly learned that Black women were not represented in the images of breast reconstruction. This led her to create Uncovered: A Breast Recognition Project, a resource that features breast cancer images and stories of Black, Indigenous, and women of colour. It was created in collaboration with Rethink Breast Cancer. The resource has been used as an education and teaching tool at the Canadian Cancer Society, Ontario Health, and at UHN. Michelle has shared it at events like World Cancer Congress in 2022, at BRA Day events, as well as local events supporting cancer awareness for the Black community.
Over the years, Michelle has shown an interest in learning more about the future of cancer care, with a keen interest in clinical trials. To support her learning, she attends local and international cancer conferences. She believes that the more you know, the more you can advocate for better. The knowledge and experiences she comes away with have helped her broaden her advocacy journey through volunteer roles at Ontario Institute for Cancer Research’s Patient and Family Advisory Council, 3CTN and Women’s College Hospital. She also serves as a patient partner on various cancer trials. As such, Michelle is excited to continue her learning and collaborations with CCTG as a member of the Breast Disease Site Committee.
"The research investments in cancer clinical trials and progressive treatment options I have seen in recent years give me hope for the future. Which is why it’s important for me to bring my voice to the development of cancer clinical trials. I want to support inclusive trial enrollment, thereby improving the generalizability of results for diverse communities," says Michelle.
Make sure to take a moment to welcome our newest Patient Representative.
Now open the CCTG PR24 ASCENDE-SBRT trial to determine whether stereotactic body radiotherapy (SBRT) can replace the current standard radiation treatment (brachytherapy boost) for men with unfavourable risk prostate cancer. SBRT is a non-invasive, high precision, less costly radiation technique that results in similar outcomes and tolerability to brachytherapy boost.
The results of the CX5/SHAPE clinical trial, published today in the New England Journal of Medicine (NEJM), conclude that a simple hysterectomy is a safe treatment option for women with low-risk early-stage cervical cancer. The Phase III international trial compared radical hysterectomy and pelvic node dissection with simple hysterectomy and pelvic node dissection.
The CIHR has announced funding, $1,828,350 over 6 years, for the CCTG PR25 trial, a metastatic prostate cancer personalized medicine study investigating the addition platinum-based chemotherapy to standard of care chemotherapy to evaluate markers believed to predict benefit.
The CCTG NE2 trial has been awarded $260,101 in the Spring CIHR grants announcement to support Canadian participation in the STOPNET clinical trial international trial, a Randomized Study of Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid-Gut Neuroendocrine Tumours.
CIHR has announced $3,056,176 in funding over 5 years, for the TACtful trial investigating a novel cell therapy using the immune system to treat people with relapsed and refractory multiple myeloma.
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS
Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade Compared to Immune Checkpoint Blockade Alone in Patients with Advanced Melanoma
STOPNET - Cessation of Somatostatin Analogues after Peptide Receptor Radionuclide Therapy in Mid, Hind-Gut and Pancreatic Tumours
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients with Alterations in DNA Damage Response Genes
Stereotactic Body Radiotherapy (SBRT) vs Conventional Palliative Radiotherapy (CRT) for Participants with Painful Bone Metastases
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
A Biomarker Sub-study of the CCTG ME.13 Duration of Anti PD-1 Therapy in Metastatic Melanoma STOP-GAP Trial
Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults with Newly Diagnosed Multiple Myeloma
Androgen Suppression Combined With Elective Nodal Irradiation and Dose Escalated Prostate Radiotherapy Treatment (ASCENDE-SBRT)
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Genitourinary Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gynecology Disease Site Committee, the Gynecology Disease Site Executive Committee, and the CCTG Patient Representative Committee.
CCTG would like to welcome our new Patient Representative Haydn Bechthold who will be supporting the Gastrointestinal Disease Site Committee.
In 2021, at the age of 22, Haydn Bechthold received a stage 3C rectal cancer diagnosis, followed by the identification of Lynch syndrome. Having endured symptoms for over four years before his diagnosis, Haydn recognized the evident gaps in care for young adult cancer patients. This diagnosis abruptly halted his soccer career in Europe, yet it sparked a new passion for patient advocacy.
The Canadian Cancer Research Alliance (CCRA) announced the recipients of its biennial awards, recognizing significant contributions to cancer research in Canada.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
N Engl J Med 388: 2159 - 2170, 2023Eskander RN;Sill MW;Beffa L;Moore RG;Hope JM;Musa FB;Mannel R;Shahin MS;Cantuaria GH;Girda E;Mathews C;Kavecansky J;Leath CA;Gien LT;Hinchcliff EM;Lele SB;Landrum LM;Backes F;O'Cearbhaill RE;Al Baghdadi T;Hill EK;Thaker PH;John VS;Welch S;Fader AN;Powell MA;Aghajanian C;
International Journal of Radiation Oncology*Biology*Physics , 2023Petersen PM;Cook AD;Sydes MR;Clarke N;Cross W;Kynaston H;Logue J;Neville P;Payne H;Parmar MKB;Parulekar W;Persad R;Saad F;Stirling A;Parker CC;Catton C;
The Oncol , 2023Gupta A;Hay AE;Crump M;Djurfeldt MS;Zhu L;Cheung MC;Shepherd LE;Chen BE;Booth CM;
N Engl J Med 388: 1645 - 1656, 2023Partridge AH;Niman SM;Ruggeri M;Peccatori FA;Azim HA;Colleoni M;Saura C;Shimizu C;Sætersdal AB;Kroep JR;Mailliez A;Warner E;Borges VF;Amant F;Gombos A;Kataoka A;Rousset-Jablonski C;Borstnar S;Takei J;Lee JE;Walshe JM;Ruíz-Borrego M;Moore HCF;Saunders C;Bjelic-Radisic V;Susnjar S;Cardoso F;Smith KL;Ferreiro T;Ribi K;Ruddy K;Kammler R;El-Abed S;Viale G;Piccart M;Korde LA;Goldhirsch A;Gelber RD;Pagani O;
J Thoracic Oncol 18: e68 - e69, 2023Piccirillo MC;Chu Q;Bradbury P;Seymour L;
Cancers 15: 1823, 2023Karamouza E;Glasspool RM;Kelly C;Lewsley LA;Carty K;Kristensen GB;Ethier JL;Kagimura T;Yanaihara N;Cecere SC;You B;Boere IA;Pujade-Lauraine E;Ray-Coquard I;Proust-Lima C;Paoletti X;
Supportive Care in Cancer 31: 256, 2023Mian H;Ringash J;Meyer R;Hay AE;Shepherd L;Djurfeldt M;Winter JN;Sussman J;Pater J;Chen BE;Prica A;